CliffBio
biologic

Tivdak

tisotumab vedotin-tftv

Loss of exclusivity—loss of exclusivity
CompanySeagen →See this company's full patent-cliff portfolio

Drug detail

Brand nameTivdak
Active ingredienttisotumab vedotin-tftv
Strength40MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Seagen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.